Cargando…

In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer

Breast cancer is the most frequently diagnosed cancer in women and the second most common cancer overall, with nearly [Formula: see text] million new cases worldwide every year. Breast cancer patients need accurate tools for early diagnosis and to improve treatment. Biomarkers are increasingly used...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazo, Claudia, Orue-Etxebarria, Estibaliz, Zabalza, Ignacio, Vivanco, Maria d. M., Kypta, Robert M., Beristain, Andoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316458/
https://www.ncbi.nlm.nih.gov/pubmed/30558303
http://dx.doi.org/10.3390/cancers10120517
_version_ 1783384534550577152
author Mazo, Claudia
Orue-Etxebarria, Estibaliz
Zabalza, Ignacio
Vivanco, Maria d. M.
Kypta, Robert M.
Beristain, Andoni
author_facet Mazo, Claudia
Orue-Etxebarria, Estibaliz
Zabalza, Ignacio
Vivanco, Maria d. M.
Kypta, Robert M.
Beristain, Andoni
author_sort Mazo, Claudia
collection PubMed
description Breast cancer is the most frequently diagnosed cancer in women and the second most common cancer overall, with nearly [Formula: see text] million new cases worldwide every year. Breast cancer patients need accurate tools for early diagnosis and to improve treatment. Biomarkers are increasingly used to describe and evaluate tumours for prognosis, to facilitate and predict response to therapy and to evaluate residual tumor, post-treatment. Here, we evaluate different methods to separate Diaminobenzidine (DAB) from Hematoxylin and Eosin (H&E) staining for Wnt-1, a potential cytoplasmic breast cancer biomarker. A method comprising clustering and Color deconvolution allowed us to recognize and quantify Wnt-1 levels accurately at pixel levels. Experimental validation was conducted using a set of 12,288 blocks of [Formula: see text] pixels without overlap, extracted from a Tissue Microarray (TMA) composed of 192 tissue cores. Intraclass Correlations (ICC) among evaluators of the data of [Formula: see text] , [Formula: see text] , [Formula: see text] and [Formula: see text] for each Allred class and an average ICC of [Formula: see text] among evaluators and automatic classification were obtained. Furthermore, this method received an average rating of [Formula: see text] out of 5 in the Wnt-1 segmentation process from the evaluators.
format Online
Article
Text
id pubmed-6316458
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63164582019-01-09 In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer Mazo, Claudia Orue-Etxebarria, Estibaliz Zabalza, Ignacio Vivanco, Maria d. M. Kypta, Robert M. Beristain, Andoni Cancers (Basel) Article Breast cancer is the most frequently diagnosed cancer in women and the second most common cancer overall, with nearly [Formula: see text] million new cases worldwide every year. Breast cancer patients need accurate tools for early diagnosis and to improve treatment. Biomarkers are increasingly used to describe and evaluate tumours for prognosis, to facilitate and predict response to therapy and to evaluate residual tumor, post-treatment. Here, we evaluate different methods to separate Diaminobenzidine (DAB) from Hematoxylin and Eosin (H&E) staining for Wnt-1, a potential cytoplasmic breast cancer biomarker. A method comprising clustering and Color deconvolution allowed us to recognize and quantify Wnt-1 levels accurately at pixel levels. Experimental validation was conducted using a set of 12,288 blocks of [Formula: see text] pixels without overlap, extracted from a Tissue Microarray (TMA) composed of 192 tissue cores. Intraclass Correlations (ICC) among evaluators of the data of [Formula: see text] , [Formula: see text] , [Formula: see text] and [Formula: see text] for each Allred class and an average ICC of [Formula: see text] among evaluators and automatic classification were obtained. Furthermore, this method received an average rating of [Formula: see text] out of 5 in the Wnt-1 segmentation process from the evaluators. MDPI 2018-12-15 /pmc/articles/PMC6316458/ /pubmed/30558303 http://dx.doi.org/10.3390/cancers10120517 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mazo, Claudia
Orue-Etxebarria, Estibaliz
Zabalza, Ignacio
Vivanco, Maria d. M.
Kypta, Robert M.
Beristain, Andoni
In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer
title In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer
title_full In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer
title_fullStr In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer
title_full_unstemmed In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer
title_short In Silico Approach for Immunohistochemical Evaluation of a Cytoplasmic Marker in Breast Cancer
title_sort in silico approach for immunohistochemical evaluation of a cytoplasmic marker in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316458/
https://www.ncbi.nlm.nih.gov/pubmed/30558303
http://dx.doi.org/10.3390/cancers10120517
work_keys_str_mv AT mazoclaudia insilicoapproachforimmunohistochemicalevaluationofacytoplasmicmarkerinbreastcancer
AT orueetxebarriaestibaliz insilicoapproachforimmunohistochemicalevaluationofacytoplasmicmarkerinbreastcancer
AT zabalzaignacio insilicoapproachforimmunohistochemicalevaluationofacytoplasmicmarkerinbreastcancer
AT vivancomariadm insilicoapproachforimmunohistochemicalevaluationofacytoplasmicmarkerinbreastcancer
AT kyptarobertm insilicoapproachforimmunohistochemicalevaluationofacytoplasmicmarkerinbreastcancer
AT beristainandoni insilicoapproachforimmunohistochemicalevaluationofacytoplasmicmarkerinbreastcancer